Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amrita Krishnan

Showing results (71-80 of 114) with videos related to

Pageof 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trialPaul G Richardson, Jeff Wolf, Andrzej Jakubowiak, et al.
Blood|January 6, 2018
Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myelomaEnrico Caserta, Junie Chea, Megan Minnix, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2003
Interleukin-2 after autologous stem-cell transplantation for adult patients with acute myeloid leukemia in first complete remissionAnthony S Stein, Margaret R O'Donnell, Marilyn L Slovak, et al.
American Journal of Hematology|May 14, 2022
Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myelomaAnita D'Souza, Ruta Brazauskas, Edward A Stadtmauer, et al.
Molecular Therapy Oncolytics|March 19, 2021
Oncolytic herpes simplex virus infects myeloma cells <i>in vitro</i> and <i>in vivo</i>Jayeeta Ghose, Ada Dona, Mariam Murtadha, et al.
JCI Insight|October 9, 2019
MiR-16 regulates crosstalk in NF-κB tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophagesJihane Khalife, Jayeeta Ghose, Marianna Martella, et al.
American Journal of Hematology|May 20, 2026
Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World AnalysisMurali Janakiram, Carlyn R Tan, Hira Mian, et al.
Blood Cancer Journal|February 11, 2022
Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)Angela Dispenzieri, Amrita Krishnan, Bonnie Arendt, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 29, 2017
Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse SurvivalMyo Htut, Anita D'Souza, Amrita Krishnan, et al.
Blood|June 15, 2016
Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trialJoseph C Alvarnas, Jennifer Le Rademacher, Yanli Wang, et al.
Pageof 12

Showing results (71-80 of 114) with videos related to

Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trialPaul G Richardson, Jeff Wolf, Andrzej Jakubowiak, et al.
Blood|January 6, 2018
Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myelomaEnrico Caserta, Junie Chea, Megan Minnix, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2003
Interleukin-2 after autologous stem-cell transplantation for adult patients with acute myeloid leukemia in first complete remissionAnthony S Stein, Margaret R O'Donnell, Marilyn L Slovak, et al.
American Journal of Hematology|May 14, 2022
Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myelomaAnita D'Souza, Ruta Brazauskas, Edward A Stadtmauer, et al.
Molecular Therapy Oncolytics|March 19, 2021
Oncolytic herpes simplex virus infects myeloma cells <i>in vitro</i> and <i>in vivo</i>Jayeeta Ghose, Ada Dona, Mariam Murtadha, et al.
JCI Insight|October 9, 2019
MiR-16 regulates crosstalk in NF-κB tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophagesJihane Khalife, Jayeeta Ghose, Marianna Martella, et al.
American Journal of Hematology|May 20, 2026
Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World AnalysisMurali Janakiram, Carlyn R Tan, Hira Mian, et al.
Blood Cancer Journal|February 11, 2022
Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)Angela Dispenzieri, Amrita Krishnan, Bonnie Arendt, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 29, 2017
Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse SurvivalMyo Htut, Anita D'Souza, Amrita Krishnan, et al.
Blood|June 15, 2016
Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trialJoseph C Alvarnas, Jennifer Le Rademacher, Yanli Wang, et al.
Pageof 12